Skip to main content

Ciaramella Giuseppe's Form 4 filing

Beam Therapeutics Inc. (BEAM) · filed Dec 22, 2021

Accession no.
0000899243-21-049422
Filed
Dec 22, 2021
Trade date
Dec 20-21, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.52M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ciaramella GiuseppeCIK 0001786322Officer (President & CSO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 20, 2021Common StockMOption exerciseAcquired+4,289$7.22+$30,966.5867,062Direct
Dec 20, 2021Common StockSSaleDisposed−4,289$85.20F3−$365,422.862,773Direct
Dec 21, 2021Common StockMOption exerciseAcquired+25,104$7.22+$181,250.8887,877Direct
Dec 21, 2021Common StockSSaleDisposed−16,456$85.38F4−$1,405,013.2871,421Direct
Dec 21, 2021Common StockSSaleDisposed−8,648$86.29F5−$746,235.9262,773Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 20, 2021Common StockMOption exerciseDisposed−4,289$0.00$0117,357Direct
Dec 21, 2021Common StockMOption exerciseDisposed−25,104$0.00$092,253Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.69, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.99, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.00 to $86.74, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)